华润三九医药股份有限公司 现金理财管理制度 （2025 年 12 月修订） 第一章 总则 第一条 目的 为规范华润三九医药股份有限公司（下称"华润三九" 或"公司"）的现金理财管理，提高资金运作效率，防范现 金理财决策和执行过程中的相关风险，提升公司经济效益， 根据《中华人民共和国公司法》《中华人民共和国证券法》 《企业内部控制基本规范》《华润三九医药股份有限公司章 程》（下称《公司章程》）等相关规定，结合公司实际情况， 特制定本制度。 第二条 定义 现金理财管理是指华润三九以提高资金使用效率和收 益水平为目标，对自有闲置资金通过投资短期银行理财（含 银行非保本浮动收益型理财产品）、银行结构性存款及其他 短期投资和理财工具进行运作和管理，在确保安全性、流动 性的基础上实现现金资产保值增值的过程。 第三条 原则 本制度适用于华润三九及其合并范围内的控股子公司。 第二章 现金理财基本要素 第五条 现金理财的主体 华润三九的现金理财主体为华润三九总部，原则上所有 下属企业不得擅自进行现金理财业务。如下属企业确有现金 理财业务需求，则需履行相应审批流程后方可进行现金理财 业务。 （一）现金理财管理应遵循安全性、流动性 ...

股票代码：000999 股票简称：华润三九 编号：2025—091 华润三九医药股份有限公司 2025 年第七次临时股东会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要提示： 1、本次股东会无否决议案。 3、本次股东会由公司董事会召集，董事长邱华伟先生主持。公司董事、监事、部分高 级管理人员及见证律师出席了本次会议。 4、本次股东会的召开符合《公司法》《上市公司股东会规则》《深圳证券交易所股票 上市规则》及《公司章程》等法律、法规及规范性文件的规定。 二、提案审议和表决情况 （一） 表决方式：现场书面表决及网络投票 （二） 表决结果 1、关于 2026 年度日常关联交易预计金额的议案 2、本次股东会不涉及变更前次股东会已通过的决议。 一、会议召开和出席情况 1、华润三九医药股份有限公司 2025 年第七次临时股东会采用现场投票和网络投票相结 合的方式召开。现场会议于 2025 年 12 月 26 日下午 14:30 在华润三九医药工业园综合办公 中心 107 会议室召开。同时，本次股东会通过深圳证券交易所交易系统投票的时间为 2025 年 12 ...

上海市锦天城（深圳）律师事务所 关于 华润三九医药股份有限公司 2025 年第七次临时股东会 之 法律意见书 上海市锦天城（深圳）律师事务所 地址：深圳市福田中心区福华三路卓越世纪中心 1 号楼 21、22、23 层 2025 年第七次临时股东会的 法律意见书 致：华润三九医药股份有限公司 上海市锦天城（深圳）律师事务所（以下简称"本所"）接受华润三九医药 股份有限公司（以下简称"公司"）委托，就公司召开 2025 年第七次临时股东 会的有关事宜，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《上市公司股东会规则》等有关法律、法规、规章和其他规范性文件以及《华润 三九医药股份有限公司章程》（以下简称"《公司章程》"）的有关规定，出具 本法律意见书。 电话：0755-82816698 传真：0755-82816898 邮编：518000 上海市锦天城（深圳）律师事务所 法律意见书 上海市锦天城（深圳）律师事务所 关于华润三九医药股份有限公司 为出具本法律意见书，本所律师对本次股东会所涉及的相关事项进行了必要 的核查和验证，审查了本所律师认为出具本法律意见书所需审查的相关文件、资 料，并现场参加了公司 ...

Investment Rating - The report suggests a positive outlook for the pharmacy and traditional Chinese medicine sectors, anticipating a recovery in 2026 after a weak performance in 2025 [2][5]. Core Insights - The pharmacy sector is expected to benefit from market consolidation, with leading companies likely to increase their market share through mergers and acquisitions during the industry clearing phase [3][11]. - The traditional Chinese medicine sector is projected to stabilize and potentially recover, driven by an increase in flu incidence and the upcoming update of the essential drug list [57][60]. Summary by Sections Pharmacy Sector - **Market Review**: The pharmacy sector faced significant challenges in 2025, with a decline in same-store sales and an overall reduction in the number of operating stores since Q4 2024 [5][20]. - **Policy Environment**: Regulatory measures are promoting a more compliant and healthier industry ecosystem, which is expected to benefit leading companies [14][15]. - **Market Size**: In the first ten months of 2025, the sales scale of physical pharmacies was 501.3 billion yuan, a year-on-year decrease of 1.6%, primarily due to a decline in non-pharmaceutical sales [16][21]. - **Competitive Landscape**: The number of pharmacies in China reached approximately 684,000 by the end of 2024, with a notable increase in store closures, particularly among smaller chains [20][24]. - **Marginal Performance**: There has been a slight recovery in retail sales data, with leading companies showing improved performance through cost reduction and efficiency measures [32][34]. - **Outlook for 2026**: Focus on market consolidation and the development of non-pharmaceutical products is recommended, as leading companies are expected to enhance their market share [44][52]. Traditional Chinese Medicine Sector - **Market Review**: The traditional Chinese medicine sector experienced overall weak performance in 2025, with some companies seeing temporary valuation increases due to innovative pipelines [57][58]. - **In-Hospital Opportunities**: The upcoming update of the essential drug list is expected to benefit companies with products that have the potential to be included [60]. - **Out-of-Hospital Opportunities**: An increase in flu incidence in Q4 2025 is anticipated to aid in inventory digestion, with some companies expected to see improved performance [60]. - **High Dividend Stocks**: Companies such as Lingrui Pharmaceutical, Jichuan Pharmaceutical, and Dong'e Ejiao are highlighted as stable high-dividend investment opportunities [60].

Market Performance - The Chinese medicine sector rose by 0.35% on December 25, with Wanbangde leading the gains [1] - The Shanghai Composite Index closed at 3959.62, up 0.47%, while the Shenzhen Component Index closed at 13531.41, up 0.33% [1] Top Gainers in Chinese Medicine Sector - Wanbangde (002082) closed at 13.42, up 10.00% with a trading volume of 221,500 shares and a transaction value of 286 million yuan [1] - ST Changyao (300391) closed at 1.53, up 5.52% with a trading volume of 469,000 shares and a transaction value of 71.61 million yuan [1] - Huasen Pharmaceutical (002907) closed at 15.57, up 4.01% with a trading volume of 62,100 shares and a transaction value of 96.15 million yuan [1] Market Trends and Capital Flow - The Chinese medicine sector experienced a net outflow of 130 million yuan from institutional investors, while retail investors saw a net inflow of 163 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Wanbangde had a net inflow of 30.98 million yuan from institutional investors, but a net outflow of 30.35 million yuan from retail investors [3] - Jiaying Pharmaceutical (002198) saw a net inflow of 16.25 million yuan from institutional investors, while retail investors had a net outflow of 9.67 million yuan [3] - Kangmei Pharmaceutical (600518) experienced a net inflow of 15.73 million yuan from institutional investors, with retail investors withdrawing 4.15 million yuan [3]

Core Viewpoint - China Resources Sanjiu (华润三九) is recognized as a benchmark enterprise in the self-medication (CHC) sector, maintaining a strong performance and brand recognition, while actively embracing innovation to drive growth in the pharmaceutical industry [1] Innovation Transformation - The company has intensified its innovation efforts, recently obtaining approval for the classic prescription Banxia Baizhu Tianma Decoction granules, marking another first for the company in the domestic market [2] - In 2024, several classic prescriptions have been approved for market entry, including "999 Yiqi Qingfei Granules," which has been included in the national basic medical insurance directory, addressing a gap in post-infection treatment for respiratory diseases [3][4] R&D Investment and Projects - The company has seen a compound annual growth rate of approximately 11% in R&D investment over the past six years, with a significant increase of 68.99% in the first half of 2025, amounting to 662 million yuan [7] - As of mid-2025, the company has 205 ongoing research projects, covering a wide range of areas from traditional Chinese medicine to global hot topics like GLP-1 and cell therapy [7] Strategic Collaborations - In June, the company signed a joint development agreement with Aierpu Regenerative Medicine for the HiCM-188 project, aimed at treating heart failure, which is a major health concern globally [5] - In August, a collaboration with Borui Pharmaceutical was established for the development of a dual agonist injection for metabolic diseases, targeting a significant market opportunity [5] - In September, the company received approval for a new indication for the innovative thrombolytic drug Puyouke, which is the first of its kind in China for acute ischemic stroke [6] Market Positioning and Strategy - The company is responding to national policies and the aging population by focusing on unmet clinical needs in chronic diseases and cancer, while maintaining a clinical value-oriented approach [9] - The CHC segment of the company demonstrates a comprehensive layout across various common health issues, showcasing a deep understanding of the disease spectrum in Chinese households [10] - The company is embedding a full-scenario layout strategy across more treatment areas, promoting a collaborative development model between traditional Chinese medicine, chemical drugs, and biological drugs [11] Future Outlook - The company is positioned to lead the innovation wave in China's pharmaceutical industry, with expectations for continued growth and development in the sector [12]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： ●被担保人：贝克诺顿（浙江）制药有限公司（以下简称"贝克浙江"）、昆药商业（昭通）医药有限公 司（以下简称"昭通医药"）。上述被担保人分别为华润三九医药股份有限公司（以下简称"华润三九"） 控股子公司昆药集团股份有限公司（以下简称"昆药集团"）下属全资子公司昆明贝克诺顿制药有限公司 （以下简称"贝克制药"）、昆药集团医药商业有限公司（以下简称"昆药商业"）的全资子公司，不存在 关联担保。 ●本次担保金额及已实际为其提供的担保余额：本次为上述被担保人提供的担保金额为1,000万元，累计 已实际为其提供的担保余额为1,500万元。 ●特别风险提示：本次被担保人昭通医药为资产负债率超过70%的公司，敬请投资者注意相关风险。 ■ 以上被担保人，信用状况良好，不属于失信被执行人，列示财务状况为被担保人公司单体数据。 ●是否在前期预计额度内：是 ●本次担保是否有反担保：不适用 ●对外担保逾期的累计数量：无 二、被担保公司情况 （一）基本情况 1、贝克诺顿（浙江 ...

股票代码：000999 股票简称：华润三九 编号：2025—090 华润三九医药股份有限公司 关于控股子公司昆药集团担保事项的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 重要内容提示： 一、担保情况概述 1. 担保事项履行的相关程序 为适应昆药集团及其相关下属公司业务发展需要，满足相关公司融资担保需求，经华润 三九董事会 2025 年第五次会议及 2024 年年度股东会审议通过，2025 年度昆药集团及其下 属子公司预计为昆药集团下属子公司不超过人民币 4.5615 亿元的银行融资授信业务提供连 被担保人：贝克诺顿（浙江）制药有限公司（以下简称"贝克浙江"）、昆药商业（昭 通）医药有限公司（以下简称"昭通医药"）。上述被担保人分别为华润三九医药股份 有限公司（以下简称"华润三九"）控股子公司昆药集团股份有限公司（以下简称"昆 药集团"）下属全资子公司昆明贝克诺顿制药有限公司（以下简称"贝克制药"）、昆药 集团医药商业有限公司（以下简称"昆药商业"）的全资子公司，不存在关联担保。 本次担保金额及已实际为其提供的担保余额：本次为上述被担保人提供的担保 ...

Core Insights - The core viewpoint of the article highlights the growing market for ready-to-eat ginseng products in China, driven by increasing health awareness among consumers, including not only the elderly but also young professionals and health-conscious individuals [1][10]. Industry Overview - Ready-to-eat ginseng is produced from ginseng through processes such as washing, steaming, slicing, drying, and flavoring, making it convenient for direct consumption while retaining essential nutrients [2]. - The market for ready-to-eat ginseng is projected to reach 28 billion yuan in 2024, with a year-on-year growth of 14.3% [1][10]. Development History - Historically, ginseng was consumed in its whole form, requiring complex preparation methods. The demand for convenient health supplements has led to the industrial development of ready-to-eat ginseng since 2011, driven by technological innovations and consumer upgrades [2][10]. - New technologies such as freeze-drying and bio-fermentation have been widely adopted, enhancing product quality and extending shelf life [2]. Regulatory Environment - Recent policies emphasize food safety and quality control across all stages of production, processing, and distribution of ready-to-eat ginseng, promoting a shift towards standardized and high-quality industry practices [4][5]. Industry Chain - The upstream of the ready-to-eat ginseng industry includes suppliers of raw materials like ginseng, honey, and packaging materials, while the midstream involves research, production, and processing [6]. - The downstream consists of various sales channels, including pharmacies, health product stores, and e-commerce platforms [6]. Market Competition - The ready-to-eat ginseng market is characterized by a fragmented competitive landscape, with the top five companies holding less than 40% market share in 2024 [12]. - Key players include Tongrentang, China Resources Sanjiu, and Yisheng Pharmaceutical, among others, each with distinct product offerings and market strategies [12][13]. Future Trends - The future of the ready-to-eat ginseng market will focus on standardized cultivation and innovative product forms to cater to diverse consumer needs, including portable packaging for convenience [16]. - There will be an increase in customized products targeting specific demographics, such as beauty products for women and fatigue-relief options for young professionals [16].

Core Insights - The event showcased China Resources Sanjiu's commitment to public health and its brand vision of "Caring for Public Health and Creating a Better Life" through an innovative dual venue model [2][4] - The activities attracted a wide range of participants, including group leaders, industry guests, media representatives, and employees, creating a vibrant atmosphere [2] Group 1: Brand Presentation - China Resources Sanjiu highlighted its core brand values by showcasing four major brands: 999, Tianshili, Kunming Pharmaceutical Group, and China Resources Tang [2] - The event featured well-known products such as 999 Cold Medicine and Tianshili's cardiovascular formulations, covering essential household medications and health products [2] - Interactive experiences, such as the intestinal maze game and herbal tea tastings, allowed attendees to engage with health knowledge in a fun way [2][3] Group 2: Headquarters Market - The headquarters market emphasized immersive experiences and emotional connections with media guests and surrounding communities through six unique booths [3] - Each booth offered distinct experiences, such as traditional craftsmanship combined with health products, DIY herbal sachets, and interactive games focused on gastrointestinal health [3] - The event reinforced brand memory through the "San Jiu" IP, encouraging participants to engage with the brand for customized rewards [3][4] Group 3: Brand Communication and Future Plans - The dual venue market event was an innovative attempt to communicate the brand's health philosophy and strengthen internal cohesion and community connections [4] - China Resources Sanjiu aims to continue focusing on consumer needs by organizing diverse and relatable brand activities to promote health concepts [4] - The successful execution of the brand day event enriched the format of the group's activities and deepened the brand image of "Warm Guardian" [4]